Intranasal delivery of insulin and a nitric oxide synthase inhibitor in an experimental model of amyotrophic lateral sclerosis

Neuroscience

Volumn 157, Issue 4, 2008, Pages 908-925

  Martinez, J A ^a   Francis, G J ^a   Liu, W Q ^a   Pradzinsky, N ^a   Fine, J ^b   Wilson, M ^a   Hanson, L R ^b   Frey II, W H ^b   Zochodne, D ^a   Gordon, T ^c   Toth, C ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b REGIONS HOSPITAL   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

amyotrophic lateral sclerosis; behavior testing; electrophysiology; endplate innervation; free oxygen radicals; insulin

Indexed keywords

CEDARLANE; HUMAN INSULIN; INSULIN; N(G) NITROARGININE METHYL ESTER; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE COURSE; ELECTROPHYSIOLOGY; FEMALE; MALE; MORPHOMETRICS; MOTONEURON; MOUSE; MUTATION; NERVE FIBER; NERVE FIBER TRANSECTION; NEUROTROPISM; NITRERGIC NERVE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

ACTION POTENTIALS; ADMINISTRATION, INTRANASAL; AGE FACTORS; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; INSULIN; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MOTOR NEURONS; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUTATION; NEURAL CONDUCTION; NEUROMUSCULAR JUNCTION; NG-NITROARGININE METHYL ESTER; PERIPHERAL NERVES; SIGNAL TRANSDUCTION; SPINAL CORD; SUPEROXIDE DISMUTASE;

EID: 56549102799     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.08.073     Document Type: Article

References (68)

1. Alisky J.M., and Davidson B.L. Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases. Hum Gene Ther 11 (2000) 2315-2329
2. Anneser J.M., Cookson M.R., Ince P.G., Shaw P.J., and Borasio G.D. Glial cells of the spinal cord and subcortical white matter up-regulate neuronal nitric oxide synthase in sporadic amyotrophic lateral sclerosis. Exp Neurol 171 (2001) 418-421
3. Beck M., Karch C., Wiese S., and Sendtner M. Motoneuron cell death and neurotrophic factors: basic models for development of new therapeutic strategies in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2 Suppl 1 (2001) S55-S68
4. Boillee S., and Cleveland D.W. Gene therapy for ALS delivers. Trends Neurosci 27 (2004) 235-238
5. Borasio G.D., Robberecht W., Leigh P.N., Emile J., Guiloff R.J., Jerusalem F., Silani V., Vos P.E., Wokke J.H., and Dobbins T. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-1 Study Group. Neurology 51 (1998) 583-586
6. Bruss M.D., Arias E.B., Lienhard G.E., and Cartee G.D. Increased phosphorylation of Akt substrate of 160 kDa (AS160) in rat skeletal muscle in response to insulin or contractile activity. Diabetes 54 (2005) 41-50
7. Carriedo S.G., Sensi S.L., Yin H.Z., and Weiss J.H. AMPA exposure induce mitochondrial Ca(2+) overload an ROS generation in spinal motor neurons in vitro. J Neurosci 20 (2000) 240-250
8. Cassina P., Cassina A., Pehar M., Castellanos R., Gandelman M., de León A., Robinson K.M., Mason R.P., Beckman J.S., Barbeito L., and Radi R. Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants. J Neurosci 28 16 (2008) 4115-4122
9. Coggeshall R.E., and Lekan H.A. Methods for determining numbers of cells and synapses: a case for more uniform standards of review. J Comp Neurol 364 (1996) 6-15
10. Dhanda D.S., Frey W.H., Leopold D., and Kompella U.B. Nose to brain delivery: approaches for drug deposition in the human olfactory epithelium. Drug Deliv Technol 5 (2005) 64-72
11. Dodge J.C., Haidet A.M., Yang W., Passini M.A., Hester M., Clarke J., Roskelley E.M., Treleaven C.M., Rizo L., Martin H., Kim S.H., Kaspar R., Taksir T.V., Griffiths D.A., Cheng S.H., Shihabuddin L.S., and Kaspar B.K. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Ther 16 6 (2008) 1056-1064
12. Edbladh M., Fex-Svenningsen A., Ekstrom P.A., and Edstrom A. Insulin and IGF-1I, but not IGF-1, stimulate the in vitro regeneration of adult frog sciatic sensory axons. Brain Res 641 (1994) 76-82
13. Ezzi S.A., Urushitani M., and Julien J.P. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem 102 1 (2007) 170-178
14. Federici T., and Boulis N.M. Gene-based treatment of motor neuron diseases. Muscle Nerve 33 (2006) 302-323
15. Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-Sanchez A., Khan J., Polak M.A., and Glass J.D. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 185 (2004) 232-240
16. Folli F., Bonfanti L., Renard E., Kahn C.R., and Merighi A. Insulin receptor substrate-1 (IRS-1) distribution in the rat central nervous system. J Neurosci 14 (1994) 6412-6422
17. Francis G.J., Martinez J.A., Liu W.Q., Xu K., Ayer A., Fine J., Tuor U.I., Glazher G., Hanson L.R., Frey II W.F., and Toth C. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in marine type I diabetic encephalopathy. Brain (2008) in press
18. Francis G.J., Martinez J.A., Liu W.Q., Forsyth A., Ngugen T., Ayer A., Fine J., Webber C.W., Zochodne D.W., Hanson L.R., Frey II W.H., and Toth C. Intranasal insulin ameliorates experimental diabetic neuropathy. Diabetes (2008) in press
19. Frandsen U., Bangsbo J., Langberg H., Saltin B., and Hellsten Y. Inhibition of nitric oxide synthesis by systemic N(G)-monomethyl-L-arginine administration in humans: Effects on interstitial adenosine, prostacyclin and potassium concentrations in resting and contracting skeletal muscle. J Vasc Res 37 (2000) 297-302
20. Frandsen U., Bangsbo J., Sander M., Hoffner L., Betak A., Saltin B., and Hellsten Y. Exercise-induced hyperaemia and leg oxygen uptake are not altered during effective inhibition of nitric oxide synthase with NG-nitro-L-arginine methyl ester in humans. J Physiol 531 (2001) 257-264
21. Frey D., Schneider C., Xu L., Borg J., Spooren W., and Caroni P. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci 20 (2000) 2534-2542
22. Gale K., Kerasidis H., and Wrathall J.R. Spinal cord contusion in the rat: behavioral analysis of functional neurologic impairment. Exp Neurol 88 (1985) 123-134
23. Grant G.J., Vermeulen K., Zakowski M.I., Sutin K.M., Ramanathan S., Langerman L., Weissman T.E., and Turndorf H. A rat sciatic nerve model for independent assessment of sensory and motor block induced by local anesthetics. Anesth Analg 75 (1992) 889-894
24. Guegan C., and Przedborski S. Programmed cell death in amyotrophic lateral sclerosis. J Clin Invest 111 (2003) 153-161
25. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., and Deng H.X. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
26. Hegedus J., Putman C.T., and Gordon T. Time course of preferential motor unit loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 28 2 (2007) 154-164
27. Hensley K., Mhatre M., Mou S., Pye Q.N., Stewart C., West M., and Williamson K.S. On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid Redox Signal 8 (2006) 2075-2087
28. Howland D.S., Liu J., She Y., Goad B., Maragakis N.J., Kim B., Erickson J., Kulik J., DeVito L., Psaltis G., DeGennaro L.J., Cleveland D.W., and Rothstein J.D. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A 99 (2002) 1604-1609
29. Huang C., Thirone A.C., Huang X., and Klip A. Differential contribution of insulin receptor substrates 1 versus 2 to insulin signaling and glucose uptake in l6 myotubes. J Biol Chem 280 (2005) 19426-19435
30. Huang T.J., Verkhratsky A., and Fernyhough P. Insulin enhances mitochondrial inner membrane potential and increases ATP levels through phosphoinositide 3-kinase in adult sensory neurons. Mol Cell Neurosci 28 (2005) 42-54
31. Hyun D.H., Lee M., Halliwell B., and Jenner P. Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins. J Neurochem 86 (2003) 363-373
32. Kang B.S., Ahn J.Y., Kim M.K., Kim H.J., Kang L., Lim H.C., Park K.S., Lee J.S., Seo J.S., Cha C.I., Kim S.U., Park Y.J., and Kim M. Heat shock protein 70 alters the endosome-lysosomal localization of huntingtin. Exp Mol Med 39 (2007) 38-46
33. Kaspar B.K., Llado J., Sherkat N., Rothstein J.D., and Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301 (2003) 839-842
34. Kim H.J., Im W., Kim S., Kim S.H., Sung J.J., Kim M., and Lee K.W. Calcium-influx increases SOD1 aggregates via nitric oxide in cultured motor neurons. Exp Mol Med 39 5 (2007) 574-582
35. Lai E.C., Felice K.J., Festoff B.W., Gawel M.J., Gelinas D.F., Kratz R., Murphy M.F., Natter H.M., Norris F.H., and Rudnicki S.A. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-1 Study Group. Neurology 49 (1997) 1621-1630
36. Lepore A.C., Haenggeli C., Gasmi M., Bishop K.M., Bartus R.T., Maragakis N.J., and Rothstein J.D. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res 1185 (2007) 256-265
37. Liu X.F., Fawcett J.R., Hanson L.R., and Frey W.H. The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. J Stroke Cerebrovasc Dis 13 (2004) 16-23
38. Mahadev K., Wu X., Motoshima H., and Goldstein B.J. Integration of multiple downstream signals determines the net effect of insulin on MAP kinase vs. PI 3′-kinase activation: potential role of insulin-stimulated H(2)O(2) 7. Cell Signal 16 (2004) 323-331
39. Matsumoto A., Okada Y., Nakamichi M., Nakamura M., Toyama Y., Sobue G., Nagai M., Aoki M., Itoyama Y., and Okano H. Disease progression of human SOD1 (G93A) transgenic ALS model rats. J Neurosci Res 83 1 (2006) 119-133
40. Messi M.L., Clark H.M., Prevette D.M., Oppenheim R.W., and Delbono O. The lack of effect of specific overexpression of IGF-1 in the central nervous system or skeletal muscle on pathophysiology in the G93A SOD-1 mouse model of ALS. Exp Neurol 207 1 (2007) 52-63
41. Pasinelli P., and Brown R.H. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 7 (2006) 710-723
42. Pun S., Santos A.F., Saxena S., Xu L., and Caroni P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci 9 (2006) 408-419
43. Recio-Pinto E., and Ishii D.N. Insulin and insulin-like growth factor receptors regulating neurite formation in cultured human neuroblastoma cells. J Neurosci Res 19 (1988) 312-320
44. Recio-Pinto E., Rechler M.M., and Ishii D.N. Effects of insulin, insulin-like growth factor-II, and nerve growth factor on neurite formation and survival in cultured sympathetic and sensory neurons. J Neurosci 6 (1986) 1211-1219
45. Reger M.A., Watson G.S., Frey W.H., Baker L.D., Cholerton B., Keeling M.L., Belongia D.A., Fishel M.A., Plymate S.R., Schellenberg G.D., Cherrier M.M., and Craft S. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27 (2006) 451-458
46. Reger M.A., Watson G.S., Green P.S., Wilkinson C.W., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Breitner J.C., DeGroodt W., Mehta P., and Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70 (2008) 440-448
47. Rosen D.R. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 364 (1993) 362
48. Sander M., Chavoshan B., and Victor R.G. A large blood pressure raising effect of nitric oxide synthase inhibition in humans. Hypertension 33 (1999) 937-942
49. Sasaki S., Shibata N., and Iwata M. Neuronal nitric oxide synthase immunoreactivity in the spinal cord in amyotrophic lateral sclerosis. Acta Neuropathol 101 4 (2001) 351-357
50. Shaw B.F., and Valentine J.S. How do ALS-associated mutations in superoxide dismutase 1 promote aggregation of the protein?. Trends Biochem Sci 32 2 (2007) 78-85
51. Shefner J.M., Cudkowicz M.E., and Brown Jr. R.H. Comparison of incremental with multipoint MUNE methods in transgenic ALS mice. Muscle Nerve 25 (2002) 39-42
52. Sippel J.M., Giraud G.D., and Holden W.E. Nasal administration of the nitric oxide synthase inhibitor L-NAME-induces daytime somnolence. Sleep 22 (1999) 786-788
53. Sugimoto K., Murakawa Y., and Sima A.A. Expression and localization of insulin receptor in rat dorsal root ganglion and spinal cord. J Peripher Nerv Syst 7 (2002) 44-53
54. Tam S.L., and Gordon T. Mechanisms controlling axonal sprouting at the neuromuscular junction. J Neurocytol 32 (2003) 961-974
55. Tankersley C.G., Haenggeli C., and Rothstein J.D. Respiratory impairment in a mouse model of amyotrophic lateral sclerosis. J Appl Physiol 102 3 (2007) 926-932
56. Tateno M., Sadakata H., Tanaka M., Itohara S., Shin R.M., Miura M., Masuda M., Aosaki T., Urushitani M., Misawa H., and Takahashi R. Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model. Hum Mol Genet 13 (2004) 2183-2196
57. Thorne R.G., Pronk G., Padmanabhan V., and Frey II W.H. Delivery of insulin-like growth factor-I to the brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127 (2004) 481-496
58. Toth C., Brussee V., Cheng C., and Zochodne D.W. Diabetes mellitus and the sensory neuron. J Neuropathol Exp Neurol 63 (2004) 561-573
59. Toth C., Brussee V., Martinez J.A., McDonald D., Cunningham F.A., and Zochodne D.W. Rescue and regeneration of injured peripheral nerve axons by intrathecal insulin. Neuroscience 139 (2006) 429-449
60. Toth C., Brussee V., and Zochodne D.W. Remote neurotrophic support of epidermal nerve fibres in experimental diabetes. Diabetologia 49 (2006) 1081-1088
61. Trejo J.L., Carro E., Garcia-Galloway E., and Torres-Aleman I. Role of insulin-like growth factor I signalling in neurodegenerative diseases. J Mol Med 82 (2004) 156-162
62. Veldink J.H., Bar P.R., Joosten E.A., Otten M., Wokke J.H., and van den Berg L.H. Sexual differences in onset of disease and response to exercise in a transgenic model of ALS. Neuromuscul Disord 13 (2003) 737-743
63. Vig P.J., Subramony S.H., D'Souza D.R., Wei J., and Lopez M.E. Intranasal administration of IGF-1 improves behavior and Purkinje cell pathology in SCA1 mice. Brain Res Bull 69 (2006) 573-579
64. Wengenack T.M., Holasek S.S., Montano C.M., Gregor D., Curran G.L., and Poduslo J.F. Activation of programmed cell death markers in ventral horn motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in a transgenic mouse model. Brain Res 1027 1-2 (2004) 73-86
65. White M.F. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283 (2002) E413-E422
66. Wilczak N., and de Keyser J. Insulin-like growth factor system in amyotrophic lateral sclerosis. Endocr Dev 9 (2005) 160-169
67. Xu Q.G., Li X.Q., Kotecha S.A., Cheng C., Sun H.S., and Zochodne D.W. Insulin as an in vivo growth factor. Exp Neurol 188 (2004) 43-51
68. Zochodne D.W., Verge V.M., Cheng C., Sun H., and Johnston J. Does diabetes target ganglion neurones? Progressive sensory neurone involvement in long-term experimental diabetes. Brain 124 (2001) 2319-2334